Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P37023

UPID:
ACVL1_HUMAN

ALTERNATIVE NAMES:
Activin receptor-like kinase 1; TGF-B superfamily receptor type I

ALTERNATIVE UPACC:
P37023; A6NGA8

BACKGROUND:
The protein Serine/threonine-protein kinase receptor R3, known alternatively as Activin receptor-like kinase 1, is a key regulator in the TGF-beta signaling pathway, essential for normal vascular development. It binds to BMP9/GDF2 and BMP10, initiating a cascade that regulates blood vessel formation and maintenance.

THERAPEUTIC SIGNIFICANCE:
Its association with Telangiectasia, hereditary hemorrhagic, 2, underscores its therapeutic potential. Understanding the role of Serine/threonine-protein kinase receptor R3 could open doors to potential therapeutic strategies for vascular diseases, offering hope for patients with hereditary hemorrhagic telangiectasia.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.